Organovo Holdings, Inc. Pre-Announces Preliminary Fiscal 2015 Fourth Quarter And Year End Financial Information

SAN DIEGO, April 21, 2015 -- Organovo Holdings, Inc. (NYSE MKT: ONVO) today announced preliminary financial information (unaudited) for the fourth quarter and fiscal year ended March 31, 2015.

Based on preliminary financial information for the fiscal quarter and year-ended March 31, 2015, Organovo estimates:

  • Total net revenues of approximately $268 thousand for the quarter, and approximately $571 thousand for the fiscal year
  • Total net cash utilization during fiscal 2015 fourth quarter and fiscal year ended March 31, 2015 of approximately $6.3 million and $21.1 million, respectively; and
  • The Company closed the year with cash and cash equivalents of approximately $50.1 million

BioLife Solutions Announces Preliminary Q1 2015 Revenue of $1.5 Million and Continued Product Adoption in the High Growth Regenerative Medicine Market

30% Year Over Year Proprietary Product Revenue Growth; Customer Cell Therapy Pre-Clinical Projects and Clinical Trials With Products Embedded Now Estimated at 185

BOTHELL, Wash., April 13, 2015 -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced preliminary revenue of $1.5 million for the first quarter of 2015 comprised entirely of core proprietary product revenue, representing 30% growth over the same period of 2014.

Second Sight Announces First Successful Implant of Model of Orion I Visual Cortical Prosthesis

SYLMAR, Calif., April 8, 2015 -- Second Sight Medical Products, Inc. (EYES) ("Second Sight" or "the Company"), a developer, manufacturer and marketer of implantable visual prosthetics to restore functional vision to blind patients, today announced the first successful implant of a mechanical model of the Orion(TM) I Visual Cortical Prosthesis ("Orion I") in an animal study.

The first implant was performed as part of a phase I pre-clinical study, which is designed to evaluate fit, form, stability and biocompatibility. This study, which is expected to run through the end of the year, is the first major milestone in the Company's development of the Orion I. Fully functional prototypes are expected to be completed later this year with active animal implants scheduled to begin by Q1 2016; the first human clinical trials are planned to commence by Q1 2017. Assuming positive initial results in patients and discussions with regulators, an expanded pivotal clinical trial for global market approvals is planned.

Dexcom® Introduces Apps That Enable the First Ever Continuous Glucose Monitoring (CGM) on the Apple Watch™

Now People With Diabetes and Caregivers Have Access to Life-Saving Glucose Data in a Convenient and Discreet Manner Right from their Wrist

SAN DIEGO--- Dexcom, Inc., (DXCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that its Dexcom G4® PLATINUM Continuous Glucose Monitor System with Share™ will support the Apple Watch™ when it ships to customers on April 24. As the industry’s first mobile-connected system, Dexcom CGM and its mobile apps, Share™2 and Follow, are already approved by the FDA and allow both users and “followers” to view glucose data directly on their iPhone. The Apple Watch apps from Dexcom will now enable users to monitor glucose on the Apple Watch so that people with diabetes can discreetly view their own information while parents and caregivers can conveniently view a child or loved one’s glucose data, giving them peace of mind and reassurance when they are apart.

SAPIEN 3 Valve Demonstrates Low Mortality, Excellent 30-Day Outcomes In High- And Intermediate-Risk Patients

SAN DIEGO, March 15, 2015 -- Edwards Lifesciences Corporation (EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that 30-day outcomes for high- and intermediate-risk patients treated with the SAPIEN 3 transcatheter aortic valve demonstrated the lowest all-cause mortality rates of any of the PARTNER studies, as well as excellent clinical outcomes on the other components of the primary endpoint measures of stroke and paravalvular regurgitation.  This first report of SAPIEN 3 data in the United States, and first report on intermediate risk transcatheter aortic valve replacement (TAVR) patients, was presented as part of the late-breaking clinical trials at the American College of Cardiology's (ACC) 64th Annual Scientific Session in San Diego.

Videos / Webinars

View all videos

Stockjunction Members

View All Members